Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Diluted Average) (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $127.2 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 5.19% year-over-year to $127.2 million; the TTM value through Dec 2025 reached $127.2 million, up 5.19%, while the annual FY2025 figure was $127.2 million, 5.19% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $127.2 million in Q4 2025 per ARQT's latest filing, down from $132.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $132.9 million in Q3 2025 and bottomed at $47.3 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $82.0 million, with a median of $61.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 4.77% in 2022, then soared 94.64% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $49.4 million in 2021, then rose by 11.39% to $55.0 million in 2022, then grew by 25.94% to $69.3 million in 2023, then surged by 74.53% to $121.0 million in 2024, then rose by 5.19% to $127.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $127.2 million in Q4 2025, $132.9 million in Q3 2025, and $127.0 million in Q2 2025.